How to Diagnose and Manage Horses with Glaucoma

Total Page:16

File Type:pdf, Size:1020Kb

How to Diagnose and Manage Horses with Glaucoma HOW-TO SESSION: OPHTHALMOLOGY How to Diagnose and Manage Horses With Glaucoma Erica L. Tolar, DVM, Diplomate ACVO*; and Amber L. Labelle, DVM, MS, Diplomate ACVO Authors’ addresses: Bluegrass Veterinary Vision, 2563 Todd’s Point Road, Simpsonville, KY 40067; e-mail: [email protected] (Tolar); University of Illinois Urbana-Champaign, 1008 West Hazelwood Drive, Urbana, IL 61802; e-mail: [email protected] (Labelle). *Corresponding and presenting author. © 2013 AAEP. 1. Introduction eye and pathologic changes associated with glau- Glaucoma is a painful ocular disease that often results coma. Immediately posterior to the iris is the cili- in vision loss and can be frustrating to treat.1–4 Equine ary body, which is hidden from view by the iris face glaucoma is most often secondary to chronic, recurrent even when the pupil is fully dilated. The ciliary episodes of intraocular inflammation as occur with body processes produce aqueous humor, the clear equine recurrent uveitis (ERU).1–8 Diagnosis of glau- intraocular fluid that provides metabolic support to coma requires tonometry, or measurement of the in- the posterior cornea and the internal structures of traocular pressure (IOP). Many types of portable, the eye. Aqueous humor flows from the posterior affordable tonometers are available to the veterinary chamber, through the pupil, into the anterior cham- practitioner, and tonometry is becoming more widely ber, and drains from the eye through the uveoscleral used in equine practice. Once a diagnosis of glau- or iridocorneal outflow pathways (Fig. 1).9 The iri- coma has been established, therapy options range docorneal angle is visible as an intraocular mesh- from topical and oral medications to advanced surgical work at the temporal and nasal limbus, with procedures. Referral to a veterinary ophthalmologist pectinate ligaments extending from the iris root to is appropriate for all cases of equine glaucoma. De- the corneoscleral junction (Fig. 2).10,11 Horses are termining the cause of the glaucoma and deciding on unique in that up to 50% of their aqueous humor an appropriate treatment plan is crucial to obtain the drainage is through the uveoscleral (also called “un- ultimate goal of maintaining a comfortable and visual conventional”) outflow pathway.12,13 eye. When vision has been lost and IOP is uncon- Intraocular pressure is a balance of aqueous hu- trolled, surgical procedures to ensure long-term com- mor production and aqueous humor outflow. Glau- fort, including enucleation, should be considered. coma is a series of intraocular pathologic events culminating in IOP elevation, optic nerve damage, 2. Anatomy and Pathophysiology of Glaucoma and vision loss. Elevated IOP results in decreased Knowledge of normal ocular anatomy allows the blood flow and optic nerve axoplasmic flow, ulti- practitioner to recognize abnormalities in the equine mately resulting in retinal cell death, compression of NOTES 174 2013 ր Vol. 59 ր AAEP PROCEEDINGS HOW-TO SESSION: OPHTHALMOLOGY Congenital glaucoma is present at birth and is un- likely to respond to therapy.7,8,16 Primary glau- coma in small-animal species is a heritable, bilateral condition that results from abnormal functioning of the aqueous humor outflow system. Primary glau- coma is infrequently reported in the horse. Glau- coma in horses is most often secondary to a concurrent ocular disease such as ERU, intraocular neoplasia, corneal perforation, or lens luxation.2–4,17 Although ERU is widely regarded as the most com- mon cause of glaucoma in horses, the mechanism by which ERU leads to secondary glaucoma is poorly understood.4 3. Examination Techniques The minimum equipment necessary for any equine ophthalmic examination includes a Finhoff transil- luminator, magnification head loupe, fluorescein stain, a tonometer, tropicamide,a and a retinoscope Fig. 1. The equine aqueous humor pathway. Aqueous humor is produced in the ciliary body (shaded), flows into the posterior (such as a direct ophthalmoscope or hand lens). chamber, through the pupil into the anterior chamber, and then If possible, the horse should be observed navigating drains through the iridocorneal angle or uveoscleral outflow in its environment before sedation. An obstacle pathway. course can be created with the use of large objects in the barn (such as trash cans and poles on the ground) to allow the practitioner to more critically 14 assess vision. Menace responses and dazzle re- the optic nerve, and blindness. In humans, forms flexes should also be observed before sedation. of glaucoma are recognized that result in optic nerve Ophthalmic examination should be performed in a degeneration, retinal degeneration, and vision loss dimly lit location to maximize detection of subtle without elevation in IOP. Similar forms of glau- lesions. Sedation with detomidine hydrochlorideb coma have not been documented in the horse; eleva- or xylazine hydrochloridec and an auriculopalpebral tion in IOP is thought to be the most important risk block are important for completion of a complete factor for glaucomatous optic nerve damage in d 14,15 examination. Butorphanol tartrate is not recom- equine patients. Intraocular pressure eleva- mended because it tends to result in jerky, sponta- tion typically results from obstruction of the aque- neous head movements. ous humor outflow pathway. Aqueous humor Tonometry is recommended for all horses with overproduction has not been reported in any domes- clinical signs of ophthalmic disease. Whereas seda- tic animal species and is not considered to be a cause tion with ␣-2 agonists can decrease IOP readings, an of glaucoma in the horse. auriculopalpebral block has no effect on IOP.18,19 Glaucoma in the horse is often divided into three Head position does have a critical effect on IOP; categories: primary, secondary, and congenital. lowering the head below the heart causes significant elevations in IOP.20 It is important to maintain a head position level with or above the heart while performing tonometry. Consistency is recom- mended when performing serial IOP measurements, with the use of the same sedation, nerve block, tonometer, and examiner each time to achieve max- imal comparability between measurements. Care- ful attention to technique is also important. Any excessive pressure on the globe may artificially in- crease IOP. Two types of tonometers are commercially avail- able for use in the horse: rebound and applana- tion.21–23 The rebound tonometere (Fig. 3) uses a magnetic probe that is projected at the cornea. The rebound tonometer is handheld, battery-oper- ated, and does not require daily calibration. The noise emitted from the machine while taking the Fig. 2. Photograph of a normal equine eye. The iridocorneal required six readings is very quiet and not likely to angle is visible just axial to the limbus (white arrow). Normal disturb the horse, even if not sedated. The read- pectinate ligaments are visible as a meshwork. ings are averaged within the machine and displayed AAEP PROCEEDINGS ր Vol. 59 ր 2013 175 HOW-TO SESSION: OPHTHALMOLOGY Table 1. Clinical Signs of Equine Glaucoma Acute signs Vision loss Epiphora Blepharospasm Corneal edema Conjunctival hyperemia Mydriasis Chronic signs Vision loss Epiphora Blepharospasm Buphthalmos Corneal edema Descemet’s striae Fig. 3. Photograph of rebound tonometry being performed in a Corneal ulcers patient with glaucoma. Note that the tonometer is held perpen- Lens luxation dicular to the ground, and the practitioner is using caution to Mydriasis avoid excessive digital pressure on the globe. Changes in the appearance of drainage angle (collapse, fibrosis) Retinal degeneration in an easily viewed window opposite the probe. Top- Optic nerve cupping ical anesthesia is not required. The mean intraocular pressure with the use of a TonoVet is 22.1 Ϯ 5.9 mm Hg, with a range from 10 to 34 mm Hg.23 Multiple applanation tonometers are commer- 4. Clinical Signs of Glaucoma cially availablef,g (Fig. 4). Applanation tonometers The clinical signs of glaucoma vary.1–3,7,8,17,24 Many differ from the rebound tonometer in that they mea- horses with glaucoma do not exhibit the classic signs of sure the force required to flatten the corneal surface. ocular pain, including blepharospasm and epiphora. All of the devices are handheld and portable. Ap- Acute signs often differ from chronic signs (Table 1). planation tonometers require a latex cover to protect Glaucomatous horses exhibit variable pupillary the tip of the device. Both of the listed applanation light reflex deficits. Glaucoma generally results in tonometers require use of topical anesthesia to ob- a mydriatic pupil caused by effects on the optic tain accurate readings. One advantage of an ap- nerve and iris sphincter muscle, but horses with planation tonometer is that it can be used with the concurrent intraocular inflammation may have mi- patient in any position, unlike the rebound tonome- otic pupils instead. Dyscoria, an abnormally ter, which must remain perpendicular to the patient shaped pupil, may result from posterior synechiae with the magnetic probe parallel to the ground. (adhesions between the iris and the lens capsule) The mean intraocular pressure with the use of a (Fig. 5). Posterior synechiae may result in pupil Tono-Pen is 21.0 Ϯ 5.9 mm Hg, with a range from 9 size being discordant with concurrent ocular disease to 33 mm Hg.23 (ie, a miotic pupil in an end-stage glaucoma eye). Fig. 4. Photograph of applanation tonometry being performed in Fig. 5. Photograph of the right eye of a horse with end-stage a patient with glaucoma. Note that the tonometer can be held in ERU. Note the small globe size, corneal fibrosis, dyscoria caused any plane, and the practitioner is using caution to avoid excessive by posterior synechiae, and cataract. This eye is not visual and digital pressure on the globe. has no potential to regain vision. 176 2013 ր Vol. 59 ր AAEP PROCEEDINGS HOW-TO SESSION: OPHTHALMOLOGY Fig. 6.
Recommended publications
  • Differentiate Red Eye Disorders
    Introduction DIFFERENTIATE RED EYE DISORDERS • Needs immediate treatment • Needs treatment within a few days • Does not require treatment Introduction SUBJECTIVE EYE COMPLAINTS • Decreased vision • Pain • Redness Characterize the complaint through history and exam. Introduction TYPES OF RED EYE DISORDERS • Mechanical trauma • Chemical trauma • Inflammation/infection Introduction ETIOLOGIES OF RED EYE 1. Chemical injury 2. Angle-closure glaucoma 3. Ocular foreign body 4. Corneal abrasion 5. Uveitis 6. Conjunctivitis 7. Ocular surface disease 8. Subconjunctival hemorrhage Evaluation RED EYE: POSSIBLE CAUSES • Trauma • Chemicals • Infection • Allergy • Systemic conditions Evaluation RED EYE: CAUSE AND EFFECT Symptom Cause Itching Allergy Burning Lid disorders, dry eye Foreign body sensation Foreign body, corneal abrasion Localized lid tenderness Hordeolum, chalazion Evaluation RED EYE: CAUSE AND EFFECT (Continued) Symptom Cause Deep, intense pain Corneal abrasions, scleritis, iritis, acute glaucoma, sinusitis, etc. Photophobia Corneal abrasions, iritis, acute glaucoma Halo vision Corneal edema (acute glaucoma, uveitis) Evaluation Equipment needed to evaluate red eye Evaluation Refer red eye with vision loss to ophthalmologist for evaluation Evaluation RED EYE DISORDERS: AN ANATOMIC APPROACH • Face • Adnexa – Orbital area – Lids – Ocular movements • Globe – Conjunctiva, sclera – Anterior chamber (using slit lamp if possible) – Intraocular pressure Disorders of the Ocular Adnexa Disorders of the Ocular Adnexa Hordeolum Disorders of the Ocular
    [Show full text]
  • Equine Uveitis Lauren Hughes, DVM
    New England Equine Medical & Surgical Center 15 Members Way · Dover NH 03820 · www.newenglandequine.com · 603.749.9111 Understanding Equine Uveitis Lauren Hughes, DVM One of the most common ocular diseases affecting the horse is a condition known as uveitis. This occurs when inflammation affects the uveal tract of the eye that is composed of the iris, ciliary body and choroid. This inflammation can be caused by a variety of conditions including ocular, systemic or immune mediated disease. Fig 1. Equine Eye Cross-Sectional Anatomy Understanding Uveitis In order to better understand uveitis we need to take a closer look at the causes of this relatively common disease. 1-Ocular- Any condition that affects the eye can lead to uveitis as a secondary complication. This includes trauma, corneal ulcers, intraocular tumors, and cataracts (which cause lens-induced uveitis). 2-Systemic- Many infectious diseases can also predispose a horse to development of uveitis. These diseases can be bacterial, viral, parasitic, or neoplastic, with one of the most recognized being the bacterial disease Leptospirosis. 3-Immune Mediated- The most commonly seen presentation of uveitis is an immune mediated form known as equine recurrent uveitis (ERU) or moon blindness. This disease consists of recurrent episodes of inflammation in which the immune system targets the tissues of the eye. This can be an ongoing and frustrating condition for owners as treatment is not curative and lifelong management is often necessary. This condition has been reported to affect upwards of 25% of the horse population with increased prevalence in certain breeds including Appaloosas, draft horses, and warmbloods.1 It can affect one or both eyes, with chronicity potentially leading to permanent vision deficits or blindness.
    [Show full text]
  • Neurotrophic Keratopathy and Diabetes Mellitus a Lockwood Et Al 838
    Eye (2006) 20, 837–839 & 2006 Nature Publishing Group All rights reserved 0950-222X/06 $30.00 www.nature.com/eye 1 1 2 Neurotrophic A Lockwood , M Hope-Ross and P Chell CASE SERIES keratopathy and diabetes mellitus Abstract no history of previous corneal trauma or herpes simplex infection. Ocular examination revealed Diabetes mellitus is frequently associated a best-corrected visual acuity of 6/12 in both with microvascular complications such as eyes. There was an epithelial irregularity retinopathy, nephropathy, and peripheral extending across the inferonasal quadrant of the neuropathy. Neurotrophic keratopathy occurs right cornea. A diagnosis of exposure in response to a neuropathy of the ophthalmic keratopathy was made. She was treated with division of the trigeminal nerve. Rarely has artificial tears and a month later the epithelium diabetic neurotrophic keratopathy been had healed. A year later, an epithelial defect in described. This paper discusses the the same area was seen at follow-up. Again she ophthalmic histories of three patients who was asymptomatic and the visual acuity was presented with diabetic neurotrophic unchanged. Decreased corneal sensation was keratopathy. In one patient the corneal noted using a cotton swab to touch the ulceration was the sole presenting feature of peripheral and central cornea. A diagnosis of his diabetes. We discuss the need for increased diabetic neurotrophic keratopathy was made. vigilance in the ophthalmic community for She was treated with ocular lubricants. After suspecting diabetes in patients with 6 months, the defect had increased in size to unexplained corneal epithelial disease. 5.5 mm. There was associated corneal Eye (2006) 20, 837–839.
    [Show full text]
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • AZARGA, INN-Brinzolamide/Timolol
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT AZARGA 10 mg/ml + 5 mg/ml eye drops, suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of suspension contains 10 mg brinzolamide and 5 mg timolol (as timolol maleate). Excipient with known effect: One ml of suspension contains 0.10 mg benzalkonium chloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, suspension (eye drops) White to off-white uniform suspension, pH 7.2 (approximately). 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction (see section 5.1). 4.2 Posology and method of administration Posology Use in adults, including the elderly The dose is one drop of AZARGA in the conjunctival sac of the affected eye(s) twice daily. When using nasolacrimal occlusion or closing the eyelids, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity (see section 4.4). If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye (s) twice daily. When substituting another ophthalmic antiglaucoma medicinal product with AZARGA, the other medicinal product should be discontinued and AZARGA should be started the following day. Special populations Paediatric population The safety and efficacy of AZARGA in children and adolescents aged 0 to 18 years have not yet been established.
    [Show full text]
  • Leptospirosis Associated Equine Recurrent Uveitis Answers to Your Important Questions What Is Leptospirosis Associated Equine Recurrent Uveitis (LAERU)?
    Lisa Dauten, DVM Tri-State Veterinary Services LLC " Leptospirosis Associated Equine Recurrent Uveitis Answers to your Important Questions! What is Leptospirosis Associated Equine Recurrent Uveitis (LAERU)? Let’s start by breaking down some terminology.! Uveitis- inflammation of the uvea. Resulting in cloudiness of the eye, pain, and potential blindness. Also know as “Moon Blindness”. Caused by trauma, infection, or corneal disease.! Uvea- part of the eye containing the iris, ciliary body, and choroid. It keeps the lens of the eye in place, maintains fluid in the eye, and keeps things in the blood from entering the inside of the eye (blood-ocular barrier). ! Recurrent Uveitis- inflammation of the uvea that sporadically reoccurs through out a horses life time. Each time there is a reoccurring episode, the damage to the eye is made worse, eventually leading to permanent damage and potential blindness. ! Leptospirosis- bacteria found in the environment shed in the urine of wildlife and livestock. Horses usually are exposed when grazing pastures or drinking from natural water sources.! LAERU- Recurrent Uveitis in horses caused by Leptospirosis.! What are the clinical signs of Uveitis? Uveitis can come on very suddenly. A lot of times horses present with severe pain in the eye, tearing, squinting, and rubbing face. The eye itself is cloudy, white or blue in color. Sometimes the signs are not as dramatic. The color change of the eye may progress slowly. In these cases, horse owners may mistake the changes for cataracts.! What do I do if I think my horse has Uveitis? Call your veterinarian to request an appointment.
    [Show full text]
  • Equine Recurrent Uveitis Slowly Releases Medication Over a Period of (ERU) Several Years
    Treatment ABOUT THE COLLEGE OF VETERINARY MEDICINE Treatment for uveitis in general depends upon the underlying cause as well as Ranked third in the nation among the severity of the symptoms. In most colleges of veterinary medicine by cases, the eye is treated with topical anti- U.S. News & World Report, NC State’s inflammatories and a pupil-dilating agent to College of Veterinary Medicine is a decrease the pain and inflammation. Oral driving force in veterinary innovation. anti-inflammatories such as Banamine® From our leadership in understanding (Flunixin meglumine) are also instituted, and and defining the interconnections in select cases bodily injections of steroids between animal and human health, to may be necessary. While these treatments groundbreaking research in areas like are helpful in subsiding the inflammation equine health, and our commitment to and pain - they’re not ideal for long-term training the next generation of veterinary use. If infectious disease is suspected to health professionals, we are dedicated be the cause, laboratory tests should be to advancing animal and human health performed followed by medical treatment if from the cellular level through entire recommended. ecosystems. If a horse responds favorably to medical therapy, Cyclosporine Implants may be an option for long-term management. This is the surgical implantation of a small Cyclosporine medicated disc that’s placed deep within the pink tissue surrounding the eye (sclera), it Equine Recurrent Uveitis slowly releases medication over a period of (ERU) several years. This medication modifies the reaction to the immune system and reduces NC State Veterinary Hospital Moon Blindness; Periodic Ophthalamia inflammation.
    [Show full text]
  • Corneal Ulcers in Cats
    Corneal Ulcers in Cats 803-808-7387 www.gracepets.com The cornea is the clear, shiny membrane that makes up the surface of the eyeball. It is much like a clear window. To understand a corneal ulcer, you must first understand how the cornea is constructed. The cornea is comprised of three layers. The most superficial or outermost layer is the epithelium. This layer is comprised of many, very thin layers of cells, similar to an onion’s skin. Below the epithelium is the stroma and the deepest layer is Descemet's membrane. Because all of these layers are clear, it is not possible to see them without special stains and a microscope. Erosion through a few layers of the epithelium is called a corneal erosion or corneal abrasion. A corneal ulcer is an erosion through the entire epithelium and down into the stroma. If the erosion goes through the epithelium and stroma to the level of Descemet's membrane, a descemetocele exists. If Descemet's membrane ruptures, the liquid inside the eyeball leaks out and the eye collapses. What causes corneal ulcers? There are several causes for corneal ulcers in cats. The most common is trauma. An ulcer may result from blunt trauma, such as a cat rubbing its eye on a carpet, or due to a laceration, such as a cat-claw scratch. The second most common cause is chemical burn of the cornea. This may happen when irritating shampoo or dip gets in the eye. Less common causes of corneal ulcers include bacterial infections, viral infections, and other diseases.
    [Show full text]
  • WO 2014/066775 Al 1 May 2014 (01.05.2014) W P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/066775 Al 1 May 2014 (01.05.2014) W P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61F 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/066834 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 25 October 2013 (25.10.201 3) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/719,144 26 October 2012 (26. 10.2012) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: FORSIGHT VISION5, INC. [US/US]; 191 kind of regional protection available): ARIPO (BW, GH, Jefferson Drive, Menlo Park, CA 94025 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: RUBIN, Anne, Brody; 191 Jefferson Drive, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Menlo Park, CA 94025 (US).
    [Show full text]
  • Corneal Cross-Linking in Infectious Keratitis David Tabibian1,5*, Cosimo Mazzotta2 and Farhad Hafezi1,3,4
    Tabibian et al. Eye and Vision (2016) 3:11 DOI 10.1186/s40662-016-0042-x REVIEW Open Access PACK-CXL: Corneal cross-linking in infectious keratitis David Tabibian1,5*, Cosimo Mazzotta2 and Farhad Hafezi1,3,4 Abstract Background: Corneal cross-linking (CXL) using ultraviolet light-A (UV-A) and riboflavin is a technique developed in the 1990’s to treat corneal ectatic disorders such as keratoconus. It soon became the new gold standard in multiple countries around the world to halt the progression of this disorder, with good long-term outcomes in keratometry reading and visual acuity. The original Dresden treatment protocol was also later on used to stabilize iatrogenic corneal ectasia appearing after laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK). CXL efficiently strengthened the cornea but was also shown to kill most of the keratocytes within the corneal stroma, later on repopulated by those cells. Review: Ultraviolet-light has long been known for its microbicidal effect, and thus CXL postulated to be able to sterilize the cornea from infectious pathogens. This cytotoxic effect led to the first clinical trials using CXL to treat advanced infectious melting corneal keratitis. Patients treated with this technique showed, in the majority of cases, a stabilization of the melting process and were able to avoid emergent à chaud keratoplasty. Following those primary favorable results, CXL was used to treat beginning bacterial keratitis as a first-line treatment without any adjunctive antibiotics with positive results for most patients. In order to distinguish the use of CXL for infectious keratitis treatment from its use for corneal ectatic disorders, a new term was proposed at the 9th CXL congress in Dublin to rename its use in infections as photoactivated chromophore for infectious keratitis -corneal collagen cross-linking (PACK-CXL).
    [Show full text]
  • Immune Responses to Retinal Autoantigens and Peptides in Equine Recurrent Uveitis
    Immune Responses to Retinal Autoantigens and Peptides in Equine Recurrent Uveitis Cornelia A. Deeg,1 Bernd Kaspers,1 Hartmut Gerhards,2 Stephan R. Thurau,3 Bettina Wollanke,2 and Gerhild Wildner3 5 PURPOSE. To test the hypothesis that autoimmune mechanisms unclear. Research has focused on the identification of infec- are involved in horses in which equine recurrent uveitis (ERU) tious agents that may induce uveitis, such as bacteria, viruses, develops spontaneously. or parasites, especially on a possible role for Leptospira inter- 6–8 METHODS. Material obtained from horses treated for spontane- rogans as an initiating agent in this process. However, the ous disease by therapeutic routine vitrectomy was analyzed for concept of an infectious factor that exclusively induces and total IgG content and IgG specific for S-Antigen (S-Ag) and maintains the disease is not sufficient to explain certain aspects interphotoreceptor retinoid-binding protein (IRBP). The cellu- of the clinical course and therapeutic approaches. Because of the recurrence of inflammation,5 the positive effect of cortico- lar infiltrate of the vitreous was analyzed by differential counts 2 of cytospin preparations and flow cytometry using equine steroids, and the insufficient therapeutic success of antibiot- lymphocyte-specific antibodies. Antigen-specific proliferation ics, the concept has emerged that the disease is immune assays were performed comparing peripheral blood lympho- mediated. Therefore, ERU is of high value for studying uveitis, because horses represent the only species besides humans in cytes (PBLs) with vitreal lymphocytes by stimulation with S-Ag 9 and several S-Ag– and IRBP-derived peptides. which recurrent uveitis develops spontaneously.
    [Show full text]
  • Ocular Emergencies for the Primary Care Optometrist
    Ocular Emergencies Ocular Emergencies for the Disclosure Statement Primary Care Optometrist . Honorarium, Speaker, Consultant, Research Grant: Aerie, Alcon, Allergan, B+L, Carl Zeiss, Glaukos, Heidelberg, Novartis, Topcon, Michael Chaglasian, OD, FAAO Associate Professor Illinois Eye Institute Illinois College of Optometry [email protected] What is a “True” Emergency? “True” Emergency . Pain (vs. discomfort) . History is key to differentiating emergency versus urgency . Current or potential for: Phone or in person Vision loss Proper triage is essential Structural damage After hours protocol Needs immediate (same day) attention Your office and your specialists Medico-legal implications History Emergency Exam Vision Recent ocular disease or One or both eyes? surgery . Acuity . External examination Visual field Other diseases . Visual fields . SLE Sudden or gradual cardiac, vascular, or . Pupils Blurred or lost? autoimmune . IOP Diplopia? viruses . Ocular Motility . Fundus exam Mono or Bino Medications or recent Pain changes to medications Redness Nausea/vomiting Onset Trauma Contact lenses M. Chaglasian, OD 1 Ocular Emergencies Emergency Kit “True” Emergency . Chemical Burns . Eye shield . pH paper Alkaline . Pressure patch . Bandage CL’s . Sterile eye wash . Diamox . Central Retinal Artery Occlusion . Alger brush . Topical drops . Forceps Antibiotics NSAID’s . Golf spud . Both have extremely high risk of severe and permanent Steroids vision loss which can be prevented via immediate Cycloplegics intervention and treatment Chemical Trauma Chemical Burns . Copious irrigation anesthetic . Acid exposure speculum Only penetrate through epithelium sterile saline v tap water car battery, vinegar, and some refrigerants . Contacts can be removed after irrigation . Sweep fornices – repeatedly . Alkaline exposure Penetrates tissues more easily and . Examination after irrigation and neutralization of pH have a prolonged effect .
    [Show full text]